Loading
A phase 1/2 trial of YL201, Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07208773 by MediLink Therapeutics (Suzhou) Co., Ltd., with 260 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-01. Interventions recorded: YL201, Ivonescimab. Conditions listed: Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL201, MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares YL201, MediLink Therapeutics.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares YL201, MediLink Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/